Search - tctmd.com

Displaying 381 - 400 of 656

Sort: Relevancy | Date

News Conference News ESC 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

L.A. McKeown

September 09, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Conference News SCCT 2019

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Yael L. Maxwell

July 18, 2019

News Conference News SCCT 2019

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Yael L. Maxwell

July 16, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

Advertisement

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

TCTMD’s Top 10 Most Popular Stories for August 2019

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

CTA or Function Tests in High-risk Chest Pain and No Known CAD: Debate Goes On

Microvascular Disease Quadruples Risk of Leg Amputation

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content